1.96
price up icon12.00%   0.21
after-market After Hours: 1.82 -0.14 -7.14%
loading
Regulus Therapeutics Inc stock is traded at $1.96, with a volume of 1.27M. It is up +12.00% in the last 24 hours and up +45.19% over the past month. Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
See More
Previous Close:
$1.75
Open:
$1.71
24h Volume:
1.27M
Relative Volume:
1.21
Market Cap:
$115.93M
Revenue:
-
Net Income/Loss:
$-30.04M
P/E Ratio:
-1.2405
EPS:
-1.58
Net Cash Flow:
$-27.38M
1W Performance:
+51.94%
1M Performance:
+45.19%
6M Performance:
+17.37%
1Y Performance:
-27.94%
1-Day Range:
Value
$1.67
$2.01
1-Week Range:
Value
$1.3405
$2.05
52-Week Range:
Value
$0.8301
$2.90

Regulus Therapeutics Inc Stock (RGLS) Company Profile

Name
Name
Regulus Therapeutics Inc
Name
Phone
858-202-6300
Name
Address
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Name
Employee
34
Name
Twitter
@regulusrx
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
RGLS's Discussions on Twitter

Compare RGLS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RGLS
Regulus Therapeutics Inc
1.96 115.93M 0 -30.04M -27.38M -1.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-27-25 Upgrade Wells Fargo Equal Weight → Overweight
Aug-02-24 Initiated Oppenheimer Outperform
Mar-18-24 Initiated Leerink Partners Outperform
Mar-28-18 Initiated B. Riley FBR, Inc. Neutral
Jan-05-18 Initiated Leerink Partners Outperform
Jun-13-17 Reiterated Chardan Capital Markets Buy
Mar-06-17 Reiterated Wedbush Outperform
Jan-30-17 Downgrade Needham Buy → Hold
Jan-30-17 Downgrade Wells Fargo Outperform → Market Perform
Dec-07-16 Reiterated Chardan Capital Markets Buy
Nov-02-16 Reiterated Needham Buy
Jul-25-16 Reiterated Chardan Capital Markets Buy
Jun-28-16 Reiterated Chardan Capital Markets Buy
Jun-28-16 Reiterated FBR Capital Outperform
Jun-28-16 Reiterated Needham Buy
Jun-07-16 Reiterated Chardan Capital Markets Buy
Apr-13-16 Initiated Chardan Capital Markets Buy
Dec-04-15 Initiated Wells Fargo Outperform
Jun-09-15 Initiated Guggenheim Buy
Apr-21-15 Resumed FBR Capital Outperform
Nov-24-14 Initiated Deutsche Bank Buy
Aug-07-14 Reiterated FBR Capital Outperform
Aug-14-13 Reiterated Needham Buy
View All

Regulus Therapeutics Inc Stock (RGLS) Latest News

pulisher
09:15 AM

IMPORTANT EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire

09:15 AM
pulisher
08:00 AM

microRNA Pioneer Regulus Takes Center Stage: CEO to Reveal Latest Developments at Elite Biotech Summit - Stock Titan

08:00 AM
pulisher
Mar 31, 2025

Regulus Therapeutics Leads The Charge Among 3 Promising Penny Stocks - simplywall.st

Mar 31, 2025
pulisher
Mar 29, 2025

Wells Fargo & Company Upgrades Regulus Therapeutics (NASDAQ:RGLS) to “Overweight” - Defense World

Mar 29, 2025
pulisher
Mar 27, 2025

Wells Fargo Upgrades Regulus Therapeutics (RGLS) - Nasdaq

Mar 27, 2025
pulisher
Mar 27, 2025

Regulus Therapeutics (RGLS) Announces Promising Phase 1b Trial R - GuruFocus.com

Mar 27, 2025
pulisher
Mar 27, 2025

Regulus stock jumps after Phase 1 data update (RGLS:NASDAQ) - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

Wells Fargo Upgrades Regulus Therapeutics to Overweight From Equalweight, $6 Price Target; Share Rise - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Regulus Therapeutics Completes Phase 1b Farabursen Study in Polycystic Kidney Disease - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews

Mar 27, 2025
pulisher
Mar 27, 2025

Regulus Therapeutics (RGLS) Announces Successful Completion of its Phase 1b MAD Clinical Trial of Farabursen (RGLS8429) for the Treatment of ADPKD - StreetInsider

Mar 27, 2025
pulisher
Mar 27, 2025

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose Clinical Trial of Farabursen for the Treatment of Autosomal Dominant Polycystic Kidney Disease - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Quantisnow

Mar 27, 2025
pulisher
Mar 27, 2025

Regulus Announces Positive Phase 1b Study Results - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Dis - StreetInsider.com

Mar 27, 2025
pulisher
Mar 27, 2025

Game-Changing Clinical Data: New Drug Stops Kidney Disease Progression in Phase 1b Trial - Stock Titan

Mar 27, 2025
pulisher
Mar 23, 2025

Regulus Therapeutics Inc. (NASDAQ:RGLS) Holdings Lowered by Victory Capital Management Inc. - Defense World

Mar 23, 2025
pulisher
Mar 18, 2025

Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now - Insider Monkey

Mar 18, 2025
pulisher
Mar 18, 2025

Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from Canaccord Genuity Group - Defense World

Mar 18, 2025
pulisher
Mar 16, 2025

HC Wainwright Reaffirms “Buy” Rating for Regulus Therapeutics (NASDAQ:RGLS) - Defense World

Mar 16, 2025
pulisher
Mar 16, 2025

10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey

Mar 16, 2025
pulisher
Mar 15, 2025

Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth? - Yahoo Finance

Mar 15, 2025
pulisher
Mar 15, 2025

Regulus Therapeutics Reports Positive Trial Results and Financials - TipRanks

Mar 15, 2025
pulisher
Mar 14, 2025

Regulus: Q4 Earnings Snapshot - Bakersfield.com

Mar 14, 2025
pulisher
Mar 13, 2025

Regulus Therapeutics Q4 Operating Expenses USD 13.746 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Regulus Therapeutics Inc. SEC 10-K Report - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Regulus: Q4 Earnings Snapshot -March 13, 2025 at 04:19 pm EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates - PR Newswire

Mar 13, 2025
pulisher
Mar 13, 2025

Regulus Therapeutics (RGLS) to Release Quarterly Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Lowers Stock Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World

Mar 11, 2025
pulisher
Mar 04, 2025

AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | AceLink Therapeutics, Sanofi, DiNAQOR AG, Poxel, AceLink Therapeutics, Regulus Therapeutics, Reata Pharma - Barchart

Mar 04, 2025
pulisher
Mar 04, 2025

AKPKD Pipeline 2024: Key Companies, MOA, ROA, and Clinical - openPR

Mar 04, 2025
pulisher
Mar 04, 2025

Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference - PR Newswire

Mar 04, 2025
pulisher
Mar 03, 2025

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Mar 03, 2025
pulisher
Mar 01, 2025

Regulus Therapeutics’ (RGLS) Buy Rating Reiterated at HC Wainwright - Defense World

Mar 01, 2025
pulisher
Feb 28, 2025

RNAi Therapeutics and Technology Market Top Companies Study - openPR.com

Feb 28, 2025
pulisher
Feb 26, 2025

Promising Phase 1b Results and FDA Alignment Drive Buy Rating for Regulus Therapeutics - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Polycystic Kidney Disease Pipeline 2025: FDA Approvals - openPR.com

Feb 26, 2025
pulisher
Feb 21, 2025

Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently - Insider Monkey

Feb 21, 2025
pulisher
Feb 20, 2025

10 Cheapest Stocks Insiders Are Buying Recently - Insider Monkey

Feb 20, 2025
pulisher
Feb 09, 2025

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts - MarketBeat

Feb 09, 2025
pulisher
Feb 07, 2025

Pre-market Movers In Healthcare Sector: ACER, AZRX, RUBY, ADTX, RGLS… - RTTNews

Feb 07, 2025
pulisher
Feb 05, 2025

Checking in on Regulus Therapeutics Inc (RGLS) after recent insiders movement - Knox Daily

Feb 05, 2025
pulisher
Feb 05, 2025

Is Regulus Therapeutics Inc (NASDAQ: RGLS) Stock Worth Investing In for High Returns? - Marketing Sentinel

Feb 05, 2025
pulisher
Feb 04, 2025

RGLS’s price-to-free cash flow ratio: A closer look at its relevance - US Post News

Feb 04, 2025
pulisher
Feb 04, 2025

Regulus Therapeutics Inc (RGLS) Stock: A Year of Highs and Lows - The InvestChronicle

Feb 04, 2025
pulisher
Feb 04, 2025

Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Morningstar

Feb 04, 2025
pulisher
Feb 04, 2025

Regulus Management Takes Center Stage at Major Healthcare ConferenceKey Details Inside - Stock Titan

Feb 04, 2025
pulisher
Feb 03, 2025

Regulus Therapeutics Inc. (NASDAQ:RGLS) Director David Baltimore Acquires 19,610 Shares - MarketBeat

Feb 03, 2025
pulisher
Feb 03, 2025

Insider Buying: Regulus Therapeutics Inc. (NASDAQ:RGLS) CEO Acquires 50,000 Shares of Stock - MarketBeat

Feb 03, 2025

Regulus Therapeutics Inc Stock (RGLS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Cap:     |  Volume (24h):